Cardiac Rehabilitation and Mortality Risk Reduction in Peripheral Artery Disease at 6-Month Outcome.
cardiac rehabilitation
exercise
functional status
mortality risk
peripheral artery disease
prognostic index
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Jun 2022
20 Jun 2022
Historique:
received:
27
04
2022
revised:
06
06
2022
accepted:
14
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The management of patients with peripheral artery disease (PAD) is integrative and multidisciplinary, in which cardiac rehabilitation (CR) plays a prognostic role in terms of functional status, quality of life, and long-term impact on morbidity and mortality. We conducted a prospective cohort study on 97 patients with PAD admitted to a single tertiary referral center. Based on a prognostic index developed to stratify long-term mortality risk in PAD patients, we divided the cohort into two groups: low and low-intermediate risk group (45 cases) and high-intermediate and high risk group (52 cases). We analyzed demographics, clinical parameters, and paraclinical parameters in the two groups, as well as factors associated with cardiological reassessment prior to the established deadline of 6 months. Obesity (p = 0.048), renal dysfunction (p < 0.001), dyslipidemia (p < 0.001), tobacco use (p = 0.048), and diabetes mellitus (p < 0.001) are comorbidities with long-term prognostic value. Low-density lipoprotein cholesterol (p = 0.002), triglycerides (p = 0.032), fasting glucose (p = 0.011), peak oxygen uptake (p = 0.005), pain-free walking distance (p = 0.011), maximum walking time (p < 0.001), and maximum walking distance (p = 0.002) influence the outcome of PAD patients by being factors associated with clinical improvement at the 6-month follow-up. PAD patients benefit from enrollment in CR programs, improvement of clinical signs, lipid and carbohydrate profile, and weight loss and maintenance of blood pressure profile within normal limits, as well as increased exercise capacity being therapeutic targets.
Identifiants
pubmed: 35741309
pii: diagnostics12061500
doi: 10.3390/diagnostics12061500
pmc: PMC9222166
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Vasc Surg. 2021 May;73:107-113
pubmed: 33689759
JAMA. 2008 Jul 9;300(2):197-208
pubmed: 18612117
Eur J Vasc Endovasc Surg. 2021 Nov;62(5):768-776
pubmed: 34092489
Sci Rep. 2017 Apr 03;8:45833
pubmed: 28367968
Am J Cardiol. 2008 May 15;101(10):1423-7
pubmed: 18471453
Vasc Med. 2016 Apr;21(2):130-6
pubmed: 26850114
J Am Coll Cardiol. 2009 Mar 24;53(12):1056-62
pubmed: 19298919
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Arch Intern Med. 2007 Dec 10;167(22):2482-9
pubmed: 18071171
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
Egypt Heart J. 2021 Mar 29;73(1):31
pubmed: 33779873
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Lancet. 2006 May 27;367(9524):1747-57
pubmed: 16731270
Cochrane Database Syst Rev. 2017 Jun 30;6:CD007130
pubmed: 28665511
Vasc Med. 2019 Dec;24(6):501-510
pubmed: 31480898
Heart Vessels. 2017 Mar;32(3):295-302
pubmed: 27412398
Stroke. 2010 Sep;41(9):2102-7
pubmed: 20689082
Eur J Prev Cardiol. 2020 Jan;27(1):51-59
pubmed: 31362534
Circ Res. 2021 Jun 11;128(12):1818-1832
pubmed: 34110907
J Vasc Surg. 2007 Apr;45(4):645-654; discussion 653-4
pubmed: 17398372
Atherosclerosis. 2013 Oct;230(2):304-9
pubmed: 24075761
Circulation. 2004 Aug 10;110(6):738-43
pubmed: 15262830
Circulation. 2017 Mar 21;135(12):e726-e779
pubmed: 27840333
JAMA Netw Open. 2021 Jan 4;4(1):e2034461
pubmed: 33464320
Circulation. 2010 Jan 5;121(1):63-70
pubmed: 20026778
Eur J Cardiovasc Prev Rehabil. 2004 Aug;11(4):304-12
pubmed: 15292764
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Diabetes Care. 2019 Jan;42(1):50-54
pubmed: 30409811
Life (Basel). 2021 Mar 21;11(3):
pubmed: 33801080
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76
pubmed: 31862749
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2373-2381
pubmed: 28398564
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Am Coll Cardiol. 2019 Jul 30;74(4):498-507
pubmed: 31345423
JACC Heart Fail. 2014 Oct;2(5):447-54
pubmed: 25194293
Arch Phys Med Rehabil. 2020 Oct;101(10):1835-1838
pubmed: 32599060
J Cardiol. 2021 Nov 29;:
pubmed: 34857431
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715